Source link : https://www.newshealth.biz/health-news/is-consolidation-osimertinib-superior-in-egfr-mutated-nsclc/
TOPLINE: Consolidated osimertinib given after treatment with chemoradiation delays disease progression significantly longer in patients with EGFR-mutated, stage III non–small cell lung cancer (NSCLC) than durvalumab or observation. METHODOLOGY: Previous studies have shown consolidation durvalumab improves progression-free and overall survival in patients with stage III NSCLC, but the optimal consolidation in EGFR-mutated disease remains less […]
Author : News Health
Publish date : 2024-02-08 10:49:40
Copyright for syndicated content belongs to the linked Source.
Categories